Free tool
FAERS Monitor: Isturisa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212801 or its brand name (Isturisa, Osilodrostat Phosphate). Reports on generic versions are filed under their own applications.
Reports
2,214
Serious
1,554
70% of reports
Hospitalization
791
Death reported
294
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use376
- fatigue305
- nausea260
- death152
- adrenal insufficiency142
- headache142
- asthenia129
- diarrhoea125
- dizziness120
- decreased appetite114
- vomiting109
- cortisol decreased88
- arthralgia78
- disease progression76
- covid-1973
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2020 | 160 |
| 2021 | 148 |
| 2022 | 268 |
| 2023 | 281 |
| 2024 | 400 |
| 2025 | 544 |
| 2026 | 412 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,945 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cortisol decreasedSignal | 88 | 793.1 | 640.7 | 63,534 |
| adrenal insufficiencySignal | 142 | 112.5 | 95.8 | 15,404 |
| disease progressionSignal | 76 | 6.1 | 4.9 | 321 |
| decreased appetiteSignal | 114 | 4.7 | 3.9 | 328 |
| off label useSignal | 376 | 4.1 | 3.7 | 909 |
| covid-19Signal | 73 | 4.0 | 3.2 | 159 |
| fatigueSignal | 305 | 3.7 | 3.4 | 628 |
| astheniaSignal | 129 | 3.3 | 2.8 | 203 |
| nauseaSignal | 260 | 3.1 | 2.8 | 387 |
| dizzinessSignal | 120 | 2.3 | 1.9 | 88 |
| vomitingSignal | 109 | 2.2 | 1.8 | 72 |
| headacheSignal | 142 | 2.2 | 1.8 | 89 |
| diarrhoea | 125 | 1.8 | 1.6 | 49 |
| arthralgia | 78 | 1.8 | 1.4 | 27 |
| death | 152 | 1.7 | 1.4 | 43 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.